Bibliography
- Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008;8:935-47
- Allen CE, Li L, Peters TL, Cell-specific gene expression in langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal langerhans cells. J Immunol 2010;184:4557-67
- Badalian-Very G, Vergilio JA, Degar BA, Recent advances in the understanding of langerhans cell histiocytosis. Br J Haematol 2012;156:163-72
- Badalian-Very G, Vergilio JA, Degar BA, Recurrent BRAF mutations in langerhans cell histiocytosis. Blood 2010;116:1919-23
- Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother 2012;9:1309-22
- Favara BE, Feller AC, Pauli M, Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997;29:157-66
- Minkov M. Multisystem langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs 2011;13:75-86
- Broadbent V, Gadner H, Komp DM, Ladisch S. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 1989;17:492-5
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
- Trouillas P, Takayanagi T, Hallett M, International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11
- Ronceray L, Potschger U, Janka G, Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: effect on course and outcome. J Pediatr 2012. [Epub ahead of print]
- Minkov M, Grois N, Heitger A, Response to initial treatment of multisystem langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002;39:581-5
- Broadbent V, Gadner H. Current therapy for langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:327-38
- Donadieu J, Piguet C, Bernard F, A new clinical score for disease activity in langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:770-6
- Titgemeyer C, Grois N, Minkov M, Pattern and course of single-system disease in langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 2001;37:108-14
- Morimoto A, Ishida Y, Suzuki N, Nationwide survey of single-system single site langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2010;54:98-102
- McClain KL. Drug therapy for the treatment of langerhans cell histiocytosis. Expert Opin Pharmacother 2005;6:2435-41
- Minkov M, Steiner M, Potschger U, Reactivations in multisystem langerhans cell histiocytosis: data of the international LCH registry. J Pediatr 2008;153:700-5; 5 e1-2
- Abla O, Weitzman S, Minkov M, Diabetes insipidus in langerhans cell histiocytosis: when is treatment indicated? Pediatr Blood Cancer 2009;52:555-6
- Grois N, Fahrner B, Arceci RJ, Central nervous system disease in langerhans cell histiocytosis. J Pediatr 2010;156:873-81; 81 e1